SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Advanced Micro Devices, Inc. engages in the provision of semiconductor businesses. It operates through the following segments: Data Center, Client, Gaming, and Embedded. The Data Center segment includes server-class CPUs, GPUs, AI accelerators, DPUs, FPGAs, SmartNICs, and Adaptive SoC products. The Client segment refers to the computing platforms, which are a collection of technologies that are designed to work together to provide a more complete computing solution. The Gaming segment is a fundamental component across many products and can be found in APU, GPU, SoC or a combination of a discrete GPU with another product working in tandem. The Embedded segment focuses on the embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending after reports surfaced of potential foundry collaboration with Intel, sparking discussions about the implications for competition and domestic chip manufacturing. The community is weighing the potential benefits and risks of this partnership, with some questioning AMD's motives and others speculating about the broader strategic implications for the semiconductor industry. Bullish sentiment is fueled by anticipation of upcoming earnings and the stock's potential to reach new highs.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

CRML is trending amid speculation of a potential U.S. government stake in the company's Greenland rare earths mine, fueled by recent news reports. The community is discussing the potential for a short squeeze and comparing CRML to other government-backed plays. Investors are closely watching the stock's movements and anticipating further news or official confirmation.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood's platform is reportedly experiencing downtime, sparking frustration among users who are unable to manage their positions. The community is actively discussing the app's reliability and potential impact on their investments, with some expressing intentions to switch to alternative platforms. Amidst this, some users speculate on potential partnerships with tech companies and highlight bullish sentiment related to the broader market.

Spruce Biosciences, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. The company was founded on November 13, 2014 and is headquartered in South San Francisco, CA.

Spruce Biosciences Inc

SPRB is trending due to FDA breakthrough therapy designation for its Sanfilippo syndrome treatment, sparking discussions of a potential short squeeze given the stock's low float. The community is actively discussing the news, potential catalysts, and speculating on the stock's next move. Some investors believe the company is significantly undervalued relative to its cash position and pipeline.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

META is trending as investors grapple with its recent dip despite broader market gains, with some citing concerns over heavy AI spending and competition while others see it as a buying opportunity after the stock filled a gap from a previous earnings report. Community discussions revolve around whether the pullback is an overreaction and if the stock is poised for a bounce, with speculation about upcoming earnings and the potential impact of new AI-driven initiatives.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

LKNCY is trending as investors discuss the company's potential to surpass Starbucks, driven by its innovative approach and expansion into the U.S. market. Community members are closely watching for a breakout above the $40 mark, with some anticipating a Nasdaq relisting. Bullish sentiment is fueled by the company's strong growth in China and increasing global presence.

HIVE Digital Technologies Ltd. engages in building a bridge between the digital currency and blockchain sector and traditional capital markets. It operates data centers for computing and mining cryptocurrencies, including Bitcoin and other coins. The firm owns and operates green energy-powered data center facilities in Canada, Sweden, and Iceland. Its project includes Iceland Cryptocurrency Mining. HIVE Digital Technologies was founded on June 24, 1987 and is headquartered in San Antonio, TX.

HIVE Digital Technologies Ltd.

HIVE Digital Technologies Ltd

HIVE Digital Technologies is trending as investors discuss its undervaluation compared to peers, especially regarding its Bitcoin mining and AI infrastructure. Community members are highlighting the company's increasing hash rate, efficient operations, and expansion into high-performance computing, generating optimism about revenue growth and future potential. Some are drawing comparisons to other miners like IREN and anticipating a significant price increase soon.

Ethereum is a global, open-source platform for decentralized applications. In other words, the vision is to create a world computer that anyone can build applications in a decentralized manner; while all states and data are distributed and publicly accessible. Ethereum supports smart contracts in which developers can write code in order to program digital value. Examples of decentralized apps (dapps) that are built on Ethereum includes tokens, non-fungible tokens, decentralized finance apps, lending protocol, decentralized exchanges, and much more.  On Ethereum, all transactions and smart contract executions require a small fee to be paid. This fee is called Gas. In technical terms, Gas refers to the unit of measure on the amount of computational effort required to execute an operation or a smart contract. The more complex the execution operation is, the more gas is required to fulfill that operation. Gas fees are paid entirely in Ether (ETH), which is the native coin of the blockchain. The price of gas can fluctuate from time to time depending on the network demand.

Ethereum

Ethereum is trending as the community anticipates potential staking ETFs and discusses institutional adoption from Grayscale, Fidelity, and BlackRock. Conversations revolve around Ethereum reaching $5K soon, with some bullish investors predicting it could climb as high as $15K by the end of the year. The possibility of multiple consecutive 10% gain days is also fueling excitement.

Eos Energy Enterprises, Inc. designs, manufactures, and deploys battery storage solutions for the electricity industry. It offers the Eos Znyth DC battery system product which designs to meet the requirements of the grid-scale energy storage market. The company was founded in 2008 and is headquartered in Edison, NJ.

Eos Energy Enterprises Inc - Ordinary Shares - Class A

EOSE is trending due to renewed investor interest in energy storage solutions, particularly those supporting AI and data centers, with discussions highlighting the company's potential as a key player. Community members are actively discussing its American-made advantage, potential for a short squeeze, and comparing it to sector peers. Recent analyst upgrades and positive technical indicators appear to be contributing to the upward momentum.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is trending as the community rallies around a potential moonshot, fueled by meme-driven enthusiasm and a focus on community building. Talk centers on expressing their 'rage' and anticipation for significant upward movement, while some users highlight the coin's potential and strong community. The coin is also drawing attention from other meme coins.

statis crypto Watchlist

Bitcoin

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Ligand Pharmaceuticals and Pelthos Therapeutics rose on Thursday after the commercial launch of Zelsuvmi (berdazimer) topical gel, developed under their partnership,&nbsp;to treat a common viral skin infection.<a href="https://stocktwits.com/symbol/PTHS">Pelthos Therapeutics</a> surged 60.8% to close at $10.01 on Thursday, while&nbsp;<a href="https://stocktwits.com/symbol/LGND">Ligand Pharmaceuticals</a> gained 2.1%.The launch triggered a $5 million milestone payment to Ligand under the companies’ license agreement. Under the terms of the licensing deal, Ligand is also entitled to a 13% royalty on worldwide sales of Zelsuvmi and up to $5 million in additional commercial milestones.Ligand also holds a 56% equity stake in Pelthos following the completion of a merger between Pelthos and Channel Therapeutics on July 2.Pelthos announced the merger earlier this month, in which CHRO Merger Sub, a wholly owned subsidiary of Channel, merged with LNHC, a wholly owned subsidiary of Ligand.&nbsp;LNHC survived as a subsidiary of Channel, and the combined company is now operating under the Pelthos Therapeutics name. Concurrent with the merger, Pelthos raised $50.1 million in a private placement led by Murchinson.&nbsp;The investment included new equity as well as the cancellation of $18.8 million in previously advanced bridge capital used to support the commercial launch of Zelsuvmi.Zelsuvmi is a nitric oxide-releasing topical gel approved by the U.S. Food and Drug Administration in 2024 for the treatment of molluscum contagiosum,&nbsp;sometimes known commonly as “water warts”, in patients aged one year and older.&nbsp;It is the first prescription medication approved for at-home application by patients, parents, or caregivers. The product was developed using the nitric oxide-based Nitricil platform, now owned by Ligand.On Stocktwits, retail sentiment was ‘extremely bullish’ amid ‘extremely high’ message volume.On Stocktwits, retail sentiment for both Ligand Pharmaceuticals and Pelthos Therapeutics was ‘bullish’, with ‘high’ message volume for Ligand and ‘extremely high’ activity for Pelthos.Ligand’s stock has gained 15.3%so far in 2025, while Pelthos has surged 266.3% over the same period.See also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-threatens-canada-with-35-tariff-by-august-mulls-blanket-rates-for-others/ch8TD9uR5l4">Trump Threatens Canada With 35% Tariff By August, Mulls Blanket 15-20% Rates For Other Countries</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Ligand Pharmaceuticals (LGND) and Pelthos Therapeutics (PTHS) commercially launched Zelsuvmi (berdazimer) topical gel (Photo credit: Getty Images)

Pelthos, Ligand Gain After Launch Of First Prescription-At-Home Treatment For Water Warts

The launch triggered a $5 million milestone payment to Ligand, which also holds a 56% stake in Pelthos and is eligible for royalties and additional commercial milestones.

Equity

Shares of Channel Therapeutics Corporation (CHRO) rocketed 61% on Thursday after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://investor.ligand.com/news-and-events/press-releases/news-details/2025/Ligand-Subsidiary-Pelthos-Therapeutics-to-Combine-with-Channel-Therapeutics/default.aspx">entered</a> into a definitive merger agreement with biopharmaceutical firm Ligand Pharmaceuticals Incorporated (LGND).Under the agreement, Ligand’s wholly owned subsidiaries, Pelthos Therapeutics Inc. and LNHC, Inc., will combine with CHRO Merger Sub Inc., a wholly-owned subsidiary of Channel.Channel will acquire 100% of the issued and outstanding equity interests of Pelthos Therapeutics and LNHC, and will change its name to Pelthos Therapeutics Inc.Ligand has agreed to invest $18 million in the combined company, while a group of strategic investors led by Murchinson has agreed to invest $32 million.The transaction is expected to close in the summer of 2025.Once the transaction is completed, the combined company will trade on the NYSE American exchange under the ticker PTHS.Channel, a non-opioid pain treatment therapeutics provider, stated that the combined company will initially focus on accelerating the commercialization of Pelthos’ FDA-approved Zelsuvmi topical gel for the treatment of Molluscum contagiosum infections in adults and pediatric patients aged one year and older.Molluscum contagiosum is a poxvirus, afflicting an estimated 16.7 million people in the United States.Ligand will be entitled to a 13% royalty on worldwide sales of Zelsuvmi, the company said.The combined company will also retain Channel’s existing development programs for the treatment of various types of chronic pain, acute and chronic eye pain, and post-surgical nerve blocks, it added.Channel CEO Frank Knuettel II said that the company performed “extensive due diligence” on the Zelsuvmi market opportunity.“Strategically, it (the merger) provides the potential for near-term revenue generation from an FDA-approved drug, the opportunity to advance Channel’s existing NaV 1.7 programs, and expanded capitalization from strong, long-standing investors,” he said.“This transaction presents a compelling opportunity to launch a commercial-ready product, with significant financial backing from Murchinson, that has the potential to deliver both near and long-term value to our shareholders,” said Ligand CEO Todd Davis.On Stocktwits, retail sentiment around Ligand jumped further into the ‘extremely bullish’ territory over the past 24 hours coupled with a surge in message volume from ‘low’ to ‘extremely high’<figure class="image"><img style="aspect-ratio:648/147;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_17_at_10_29_08_AM_png_52226d4e3f.webp" alt="LGND's Sentiment Meter and Message Volume as of 10:30 a.m. ET on April 17, 2025 | Source: Stocktwits" width="648" height="147"><figcaption>LGND's Sentiment Meter and Message Volume as of 10:30 a.m. ET on April 17, 2025 | Source: Stocktwits</figcaption></figure> <a href="https://stocktwits.com/symbol/LGND">LGND stock</a> is down by about 3% this year but up by over 33% over the past 12 months.Retail sentiment around Channel, meanwhile, jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours.<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2025_04_17_at_10_29_44_AM_png_bccf41e1ea.webp" alt="CHRO's Sentiment Meter and Message Volume as of 10:30 a.m. ET on April 17, 2025 | Source: Stocktwits"><figcaption>CHRO's Sentiment Meter and Message Volume as of 10:30 a.m. ET on April 17, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/CHRO">CHRO stock</a> is up by about 172% year-to-date but down by nearly 1.5% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/lockheed-martin-stock-drops-after-cfo-jay-malave-steps-down-just-days-before-q1-earnings/chQEM9RRbfN">Lockheed Martin Stock Drops After CFO Jay Malave Steps Down Just Days Before Q1 Earnings</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

Channel Therapeutics Stock Soars On Announcement Of Subsidiary’s Merger With Ligand Pharma Units: Retail’s Elated

Under the agreement, Ligand’s wholly owned subsidiaries, Pelthos Therapeutics Inc. and LNHC, Inc. will combine with CHRO Merger Sub Inc., a wholly-owned subsidiary of Channel.

Ligand to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report fourth quarter and full year 2024 financial results before the opening of the U.S. financial markets on...

Ligand to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will present at the Oppenheimer 35th Annual...

Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) will host its Investor and Analyst Day in Boston today. The event will feature presentations from Ligand CEO Todd Davis, CFO Tavo Espinoza, and...

Ligand to Present at Stifel 2024 Healthcare Conference

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will present at the Stifel 2024 Healthcare...

Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and nine months ended September 30, 2024, and provided an operating forecast and business update...

Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will host an Investor and Analyst Day in Boston on Tuesday, December 10, 2024 from 10:30 a.m. to 12:00 p.m. Eastern Time...

Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report third quarter 2024 financial results before the opening of the U.S. financial markets on Thursday, November 7...

Critical Insights From Ligand Pharmaceuticals Analyst Ratings: What You Need To Know

Latest Ratings for LGND
 DateFirmActionFromTo Feb 2022BenchmarkMaintainsBuy Feb 2022BarclaysMaintainsOverweight Sep 2021BarclaysMaintainsOverweight
 View More Analyst Ratings for LGND...

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in Jupiter, FL.

Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B

Will PepsiCo ($PEP) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

PepsiCo Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest LGND News

LGND Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B